Evaluation of Power Doppler US Technique for the Diagnosis of Spondylarthropathy (EchoSpA)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00794404
Recruitment Status :
First Posted : November 20, 2008
Last Update Posted : October 31, 2016
Dr Maria-Atonietta D'AGOSTINO
Groupe Français d'Etude Génétique des Spondylarthropathies
French Society of Rheumatology
Information provided by (Responsible Party):
Dr Maria-Atonietta D'AGOSTINO, Groupe Français d'Etude Génétique des Spondylarthropathies
The purpose of this study is to evaluate the interest of enthesis sonography for the diagnosis of spondylarthritis, in patients with uncertain diagnosis consulting for clinical symptoms suggestive of spondylarthritis
Spondylarthritis (SPA) are the second most frequent inflammatory rheumatic disorders and, because it starts early in life and has a chronic progressive course, the impact of this disease on health resources and patient's life quality can be important. Because the characteritic signs of SPA, like radiological evidence of sacro-iliitis, appear late in time, the lag time between the onset first signs of SPA for the patient and the confirmed diagnosis can be very long (up to 8 years). Previous studies proved that patients who are affected by SPA are showing abnormal vascularization of peripheral enthesis more frequently than patients affected by other rheumatic diseases. Ultrasonography in B mode combined with power Doppler (PDUS) is a non invasive and highly sensitive toll which can detect enthesitis and abnormal vsacularization even for the patients who are not showing yet the evidence of SPA's symptomatology. Using PDUS as a early diagnosis tool could lead to the improvement of diagnostic procedures and therapeutic management of SpA and reduce the cost of diagnosis for patient and health insurances.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with a symptomatology which can lead to a SPA diagnosis but with no confirmed diagnosis yet for any rheumatic didease.
patients < 50 years old, consulting for spinal inflammatory symptoms > 3 months duration
patients consulting for arthritis or tenderness joints > 3 months duration
patients < 50 years old consulting for enthesitis or dactylitis > 3 months duration
patients with uveitis and HLA-B27 positivity
relatives of SpA patients consulting for symptoms suggestive of SpA
patient with confirmed diagnosis of rheumatic disease (included SpA)
patient protected by law (patient <18 years old, pregnant woman)
patient who can't atempt the RMI
patient who will have difficulties to complete the two years of follow-up